In addition, ZNF8 showed significant differences in stages I–IV (p < 0.05), stages I–III (p < 0.01), and stages II–III (p < 0.05), and its expression was upregulated in breast cancer tissues compared to that in normal tissues: the higher the pathological stage, the more its expression was downregulated. Here, ZNF8 is linked to breast cancer.